Bisphosphonates to prevent breast cancer recurrence

BY DEBU TRIPATHY
PUBLISHED: FEBRUARY 14, 2014
Debu Tripathy blog image

Sometimes advances in treatment come suddenly with the results of one major trial, but in the case of bisphosphonates--drugs used to treat bone thinning or bone metastases--the information has been trickling in slowly.

For over a decade, studies in early-stage breast cancer have hinted that the risk of metastatic recurrence can be lowered with bisphosphonates. We still don't know exactly how a bone-targeting drug could prevent recurrence. One clue comes from that fact that these drugs seem to lower the number of microscopic cancer cells that are sometimes seen in the bone marrow of patients--even those that may never actually develop metastases. However, patients who harbor these so called "micrometastases" do have a higher risk of developing breast cancer. It has been postulated that the bone may serves as the "soil" to support the "seed," in this case tumor cells, that can then go on to form metastases. It is therefore thought that bisphosphonates, which are known to lower the resorption and turnover of bone minerals, may therefore make the "soil" less hospitable to tumor cells.

However, large randomized clinical trials of bisphosphonate therapy using the more potent newer generation amino-bisphosphonates such as Zometa (zoledronic acid) have yielded mixed results--some showing fewer recurrences and others showing no effect at all.

Finally, a clearer picture appears to be emerging from analyzing all these trials together, as was recently done in what is called an overview (or meta-) analysis. A pooling of the results of trials that involved nearly 23,000 patients demonstrates that the main impact is in post-menopausal women, or those that have their ovaries suppressed with medical therapy. In these patients, the death rate is lowered by about 3 percent over 10 years. While this difference may seem modest, it is in the same range of what some chemotherapy treatments provide for early-stage breast cancer. It is unlikely that more trials of this nature will be done, although we still await results and updates from some of these studies. The big question will be whether the medical community (and insurance companies) will heed the results of this meta-analysis when many of the individual trials were negative. This remains to be seen as revised guidelines in this area are currently being formulated by the American Society of Clinical Oncology.

Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.
x-button
Special Feature
Share Your Art
Related Articles
BRCA Mutations May Cause Drug Resistance in Breast and Ovarian Cancer
There is a relationship between the genetics of BRCA1 and BRCA2 mutations and the risk of a patient with breast or ovarian cancer being resistant to platinum-based chemotherapy, according to recent research conducted at the Perelman School of Medicine at the University of Pennsylvania. The study’s senior author Katherine Nathanson, M.D., spoke with CURE about these findings.
Sarah Sciortino on Fertility and Sexuality in Younger Patients with Ovarian Cancer
Sarah Sciortino, MSW, LSW, Oncology Psychosocial Support Services Program Coordinator at University of Chicago Hospital, discusses the unique concerns that younger patients with ovarian cancer can face.
Caring With Confidence: Study Examines Caregiver Mastery and Patient Survival in GBM
A recent study found that the level of family caregiver mastery may have an effect on the survival of patients with glioblastoma.
Related Videos
Examining Quality of Life Issues for Patients With MPNs
Sandra Allen-Bard, MSN, ANCC, AOCNP, of Weill Cornell Medical Center, discusses the impact myeloproliferative neoplasms can have on patients' quality of life.
Elliott Winton on the Changing Landscape of MPN Treatment
Elliott Winton, M.D., researcher, physician and 2016 MPN Hero, discusses some of the drastic changes that happened over the past decade or so in the world of MPNs. 
Siddhartha Mukherjee on Increasing MPN Awareness
Siddhartha Mukherjee, M.D., Ph.D, an oncologist, researcher and Pulitzer Prize-winning science writer, discusses the increasing awareness about myeloproliferative neoplasms (MPNs).
x
//For side ad protocol